Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06028217
Other study ID # CHAPTER-1.7
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date October 1, 2023
Est. completion date December 31, 2027

Study information

Verified date August 2023
Source Ruijin Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China. The main purposes of this study are: 1. clarify the regional differences and changes over time in the pathogen spectrum and antibiotic resistance rate among HAP patients in China; 2. build a continuously optimized nationwide HAP pathogen and antibiotic resistance surveillance network; 3. identify the molecular epidemiology of common pathogens


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 4000
Est. completion date December 31, 2027
Est. primary completion date September 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Age = 18 years old. 2. Meets the clinical diagnostic criteria for HAP in the 2018 HAP/VAP guidelines. Chest X-ray or CT shows new or progressive infiltrative shadows, consolidation shadows, or ground glass shadows, combined with 2 or more of the following 3 clinical symptoms, to establish a clinical diagnosis: 1) Fever, body temperature>38 ?; 2) Purulent airway secretions; 3) Peripheral blood white blood cell count >10 × 10^9/L or <4 × 10^9/L. 3. Having qualified evidence of responsible pathogen. On the basis of clinical diagnosis, one of the following conditions should be met simultaneously: 1) Qualified lower respiratory tract secretions (neutrophil count >25/low magnification field, epithelial cell count <10/low magnification field, or a ratio of the two >2.5:1), pathogenic bacteria cultured through bronchoscopy anti pollution brush (PSB), bronchoalveolar lavage fluid (BALF), lung tissue or sterile body fluid, and consistent with clinical manifestations; 2) Pathology, cytopathology, or direct microscopic examination of lung tissue specimens showing fungi and evidence of tissue damage; 3) The serum IgM antibodies of atypical pathogens or viruses change from negative to positive, or the titers of specific IgG antibodies in both acute and recovery phases show a 4-fold or more change. During the outbreak of respiratory viruses and with a history of epidemiological contact, respiratory secretions were tested positive for corresponding virus antigens, nucleic acid tests, or virus culture. 4. obtained informed consent Exclusion Criteria: 1. Those who cannot understand and execute the investigation plan. 2. Active pulmonary tuberculosis; 3. Severely immunosuppressed patients: absolute neutrophil count <0.5× 10^9/L, CD4<200/ml.

Study Design


Intervention

Other:
prognosis status
observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary mortality at day 28 prognosis 28 days after enrollment
Secondary clinical characteristics symptoms, physical examinations, comorbidity, laboratory tests, imaging findings and treatment 0 day, 3 days, 7days, 14 days and 28 days after enrollment
Secondary pathogen molecular characteristics of responsible pathogen; antibiotic resistance of bacteria 0 day, 3 days, 7days, 14 days and 28 days after enrollment
See also
  Status Clinical Trial Phase
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT05502380 - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery Phase 3
Withdrawn NCT04462133 - Optimal Tailored Treatment for H. Pylori Infection N/A
Completed NCT03535324 - Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT) N/A
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Withdrawn NCT04230746 - Effect of Antibiotics on Urinary Microbiome Early Phase 1
Active, not recruiting NCT03865706 - Inulin for Infections in the Intensive Care Unit Phase 2
Completed NCT05391035 - The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Recruiting NCT05224401 - Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs Phase 3
Not yet recruiting NCT03855709 - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Terminated NCT03535272 - Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea Phase 3
Recruiting NCT05902299 - Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions
Recruiting NCT05293483 - The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
Recruiting NCT05561504 - Helicobacter Pylori Local Prevalence and Antibiotic Resistance
Recruiting NCT03606031 - Digestive Microbiota Transplant
Completed NCT01573195 - Merck IISP Stewardship Grant for Antibiotic Best Practices Phase 4
Not yet recruiting NCT03857295 - Infections Following NeuroSurgery (INS)
Not yet recruiting NCT03180983 - Antibiotic Use in French Nursing Home N/A